Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
GTXI's Cash to Debt is ranked higher than
96% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. GTXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GTXI' s Cash to Debt Range Over the Past 10 Years
Min: 1890.4  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
GTXI's Interest Coverage is ranked higher than
96% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GTXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GTXI' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
F-Score: 4
Z-Score: -14.06
M-Score: -4.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) 814.56
GTXI's ROE (%) is ranked higher than
100% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. GTXI: 814.56 )
Ranked among companies with meaningful ROE (%) only.
GTXI' s ROE (%) Range Over the Past 10 Years
Min: -397.59  Med: -73.61 Max: 814.56
Current: 814.56
-397.59
814.56
ROA (%) 86.33
GTXI's ROA (%) is ranked higher than
99% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. GTXI: 86.33 )
Ranked among companies with meaningful ROA (%) only.
GTXI' s ROA (%) Range Over the Past 10 Years
Min: -118.97  Med: -42.47 Max: 86.33
Current: 86.33
-118.97
86.33
ROC (Joel Greenblatt) (%) -249614.58
GTXI's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. GTXI: -249614.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GTXI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -249614.58  Med: -2350.66 Max: 522.64
Current: -249614.58
-249614.58
522.64
EBITDA Growth (3Y)(%) -42.50
GTXI's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. GTXI: -42.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GTXI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -15.6 Max: 10.4
Current: -42.5
0
10.4
EPS Growth (3Y)(%) -38.70
GTXI's EPS Growth (3Y)(%) is ranked lower than
86% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. GTXI: -38.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GTXI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.8  Med: -7.05 Max: 194
Current: -38.7
-54.8
194
» GTXI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

GTXI Guru Trades in Q3 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
Q4 2015

GTXI Guru Trades in Q4 2015

Paul Tudor Jones 34,033 sh (unchged)
» More
Q1 2016

GTXI Guru Trades in Q1 2016

Paul Tudor Jones 34,033 sh (unchged)
» More
Q2 2016

GTXI Guru Trades in Q2 2016

Paul Tudor Jones 34,033 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GTXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:KIN, OTCPK:ATRND, NAS:INFI, OTCPK:HSDT, NAS:LIFE, OTCPK:COTQF, OTCPK:DFFND, NAS:TCON, AMEX:NAVB, NAS:REPH, AMEX:MSTX, AMEX:ATNM, NAS:FATE, NAS:ZFGN, AMEX:CVM, NAS:AVEO, NAS:NEPT, NAS:CATB, NAS:KMPH, NAS:PPHM » details
Traded in other countries:GTU.Germany,
GTx Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of small molecules for treatment of cancer, including treatments for breast and prostate cancer and other medical conditions.

GTx Inc is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). It is conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The Company's advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 2.73
GTXI's Price/Owner Earnings (ttm) is ranked higher than
94% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 33.65 vs. GTXI: 2.73 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GTXI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.73  Med: 128.73 Max: 612.26
Current: 2.73
2.73
612.26
P/B 4.31
GTXI's P/B is ranked lower than
58% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. GTXI: 4.31 )
Ranked among companies with meaningful P/B only.
GTXI' s P/B Range Over the Past 10 Years
Min: 0.44  Med: 4.24 Max: 12950
Current: 4.31
0.44
12950
Current Ratio 6.19
GTXI's Current Ratio is ranked higher than
60% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. GTXI: 6.19 )
Ranked among companies with meaningful Current Ratio only.
GTXI' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.22 Max: 21.23
Current: 6.19
0.56
21.23
Quick Ratio 6.19
GTXI's Quick Ratio is ranked higher than
62% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. GTXI: 6.19 )
Ranked among companies with meaningful Quick Ratio only.
GTXI' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.22 Max: 21.22
Current: 6.19
0.56
21.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -30.70
GTXI's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. GTXI: -30.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GTXI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -65.1  Med: -16.8 Max: 0
Current: -30.7
-65.1
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.09
GTXI's Price/Net Cash is ranked higher than
56% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. GTXI: 5.09 )
Ranked among companies with meaningful Price/Net Cash only.
GTXI' s Price/Net Cash Range Over the Past 10 Years
Min: 2.7  Med: 6.93 Max: 307.67
Current: 5.09
2.7
307.67
Price/Net Current Asset Value 4.31
GTXI's Price/Net Current Asset Value is ranked higher than
59% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. GTXI: 4.31 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GTXI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.64  Med: 6.08 Max: 76.92
Current: 4.31
2.64
76.92
Price/Tangible Book 4.31
GTXI's Price/Tangible Book is ranked higher than
50% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. GTXI: 4.31 )
Ranked among companies with meaningful Price/Tangible Book only.
GTXI' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.59  Med: 5.89 Max: 58.33
Current: 4.31
2.59
58.33
Earnings Yield (Greenblatt) (%) -40.14
GTXI's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. GTXI: -40.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GTXI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -40.14  Med: 175.1 Max: 3978.9
Current: -40.14
-40.14
3978.9

More Statistics

EPS (TTM) $ -0.11
Beta2.25
Short Percentage of Float1.23%
52-Week Range $0.29 - 1.20
Shares Outstanding (Mil)141.92

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17
Revenue (Mil $)
EPS ($) -0.14 -0.15
EPS w/o NRI ($) -0.14 -0.15
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for GTXI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: GTx, Inc, VIVUS, Inc, Time Warner Inc. Jul 22 2012 
Weekly CEO Sells Highlight: GTX, Signet Group, Qlik Tech, Voxx Apr 16 2012 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2010 
GTx Inc. Reports Operating Results (10-Q) Aug 09 2010 
GTx Inc. Reports Operating Results (10-Q) May 04 2010 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2009 
GTx Inc. Reports Operating Results (10-Q) Aug 10 2009 
GTx Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
GIGABYTE Releases GeForce® GTX 1060 XTREME GAMING 6GB Graphics Card Aug 23 2016
GTX INC /DE/ Financials Aug 19 2016
GIGABYTE Releases GeForce® GTX 1060 Graphics Cards Equipped with 3GB Memory Aug 18 2016
GIGABYTE Introduces the GeForce® GTX 10 Series Gaming Laptops Aug 16 2016
Nvidia: 'GTX1080′ Will Power Them to Blow Away Q2 Estimate, Says M Science Aug 11 2016
GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 09 2016
GTx Provides Corporate Update and Reports Second Quarter 2016 Financial Results Aug 09 2016
GTx reports 2Q loss Aug 09 2016
GTx reports 2Q loss Aug 09 2016
GTx Provides Corporate Update and Reports Second Quarter 2016 Financial Results Aug 09 2016
GIGABYTE to Release GeForce® GTX 1060 G1 GAMING Graphics Card Jul 07 2016
GIGABYTE Adds Two New Models to GeForce® GTX 1070 Line Jul 07 2016
GIGABYTE Releases GeForce® GTX 1070 XTREME GAMING Graphics Card Jul 01 2016
GTX INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Jun 22 2016
GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session Jun 21 2016
Inventergy Announces Definitive Agreement With GTX Jun 17 2016
GIGABYTE Releases GeForce® GTX 1070 G1 GAMING Graphics Card Jun 17 2016
GTx, Inc. :GTXI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 Jun 08 2016
GIGABYTE Launches GeForce® GTX 1080 XTREME GAMING Graphics Card Jun 07 2016
GTx Announces Webcast of Corporate Presentation at Jefferies 2016 Global Healthcare Conference Jun 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)